ADmit Therapeutics Relocates to New State-of-the-Art Facilities Within the Almirall’s Innovation Hub "The Hive"

ADmit Therapeutics, a biotechnology company focused on developing innovative diagnostic solutions for Alzheimer's disease, today announced its relocation to new, expanded laboratory and office spaces within Almirall’s Innovation Hub "The Hive" at the existing R&D center in Sant Feliu de Llobregat.

This strategic move signifies a key milestone for ADmit Therapeutics, providing access to enhanced infrastructure and fostering even closer collaboration within the vibrant scientific ecosystem at "The Hive." The new facilities offer increased capacity and cutting-edge resources to accelerate the company's research and development efforts in the fight against Alzheimer's and other neurodegenerative diseases.

"We are thrilled to establish our new home within 'the Hive'," said Marta Barrachina, CEO and Co-Founder of ADmit Therapeutics. "This relocation not only provides us with superior facilities but also strengthens our ties with a leading pharmaceutical company, creating a synergistic environment that will undoubtedly propel our mission to bring an early diagnostic test for Alzheimer's disease to patients sooner."

"Welcoming ADmit to The Almirall Innovation Hub marks a pivotal milestone in our journey towards open collaboration and becoming part of a dynamic science exchange ecosystem - one that fosters industry synergies and strategic partnerships to help transform lives", said Marc Soriano, Executive Director R&D Project, Portofolio and Partner Excellence at Almirall.

The move is effective immediately, with all operations now fully transitioned to the new location after the on-site audit by regulatory agencies.